Patents Assigned to VIIV Healthcare Company
  • Publication number: 20220213121
    Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
    Type: Application
    Filed: January 27, 2022
    Publication date: July 7, 2022
    Applicants: Shionogi & Co., Ltd., ViiV Healthcare Company
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
  • Publication number: 20220119417
    Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Application
    Filed: August 6, 2021
    Publication date: April 21, 2022
    Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
  • Publication number: 20220117993
    Abstract: The invention relates to compounds of the Formula: salts thereof, pharmaceutical compositions thereof, combinations thereof, as well as therapeutic methods of treatment and prevention.
    Type: Application
    Filed: August 8, 2019
    Publication date: April 21, 2022
    Applicants: GlaxoSmithKline Intellectual Property (No. 2) Limited, VIIV Healthcare Company
    Inventors: John Franklin MILLER, David TEMELKOFF, Emile Johann VELTHUISEN, Martha Alicia DE LA ROSA, Lita SUWANDI, B. Narasimhulu NAIDU
  • Publication number: 20220096487
    Abstract: Invented are methods for treating HIV in a human in need thereof which comprises the administration of a therapeutically effective amount of a combination of dolutegravir or a pharmaceutically acceptable salt thereof and lamivudine or a pharmaceutically acceptable salt thereof, to such human.
    Type: Application
    Filed: February 3, 2020
    Publication date: March 31, 2022
    Applicant: VIIV HEALTHCARE COMPANY
    Inventor: Martin John GARTLAND
  • Patent number: 11267823
    Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: March 8, 2022
    Assignees: SHIONOGI & CO., LTD., VIIV HEALTHCARE COMPANY
    Inventors: Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
  • Patent number: 11224597
    Abstract: The present Invention relates to pharmaceutical compositions of (3S,11aR)—N-[(2,4-difluorophenyhmethyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: January 18, 2022
    Assignee: ViiV Healthcare Company
    Inventors: Deepak B. Mundhra, Rennan Pan
  • Publication number: 20210323993
    Abstract: The invention relates to compounds of Formulae (I), (Ia), (II) and (IIa), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
    Type: Application
    Filed: August 28, 2019
    Publication date: October 21, 2021
    Applicants: GlaxosmithKline Intellectual Property (No. 2) Limited, ViiV Healthcare Company
    Inventors: John MILLER, David TEMELKOFF, Emile Johann VELTHUISEN, Martha Alicia DE LA ROSA, Lisa SUWANDI
  • Patent number: 11117904
    Abstract: The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: September 14, 2021
    Assignees: ViiV Healthcare Company, Board of Regents of University of Nebraska
    Inventors: Benson J. Edagwa, Howard E. Gendelman, Brian Alvin Johns
  • Patent number: 10927129
    Abstract: The present invention is directed to N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide of the formula: or a pharmaceutically acceptable salt or stereoisomer thereof, and pharmaceutical compositions comprising the same. The present invention has HIV integrase inhibitory activity.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: February 23, 2021
    Assignees: SHINOGI & CO., LTD., VIIV HEALTHCARE COMPANY
    Inventors: Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
  • Publication number: 20210009609
    Abstract: The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 14, 2021
    Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
  • Publication number: 20200407393
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: March 6, 2019
    Publication date: December 31, 2020
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED, VIIV HEALTHCARE COMPANY
    Inventors: Martha Alicia DE LA ROSA, John Franklin MILLER, David TEMELKOFF, Emile Johann VELTHUISEN
  • Publication number: 20200339598
    Abstract: The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.
    Type: Application
    Filed: July 9, 2020
    Publication date: October 29, 2020
    Applicants: Shionogi & Co., Ltd., ViiV Healthcare Company
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
  • Publication number: 20200299309
    Abstract: The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.
    Type: Application
    Filed: June 10, 2020
    Publication date: September 24, 2020
    Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Richard M DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
  • Patent number: 10758531
    Abstract: Methods for treating HIV or AIDS in a human are provided using two drug regimens comprising a bictegravir and rilpivirine, as well as compositions containing such compounds.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: September 1, 2020
    Assignee: ViiV Healthcare Company
    Inventor: William R. Spreen
  • Patent number: 10654871
    Abstract: The present invention relates to the preparation of a compound of formula VIII:
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: May 19, 2020
    Assignee: ViiV Healthcare Company
    Inventors: Steven N. Goodman, Huan Wang, Douglas Mans, Matthew Kowalski
  • Patent number: 10654870
    Abstract: The present invention relates to the preparation of compounds of formula IV: wherein R is alkyl, aryl or benzyl.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: May 19, 2020
    Assignee: ViiV Healthcare Company
    Inventors: Steven N. Goodman, Huan Wang, Douglas Mans, Matthew Kowalski
  • Patent number: 10647728
    Abstract: The present invention relates to the preparation of a compound of formula VI:
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: May 12, 2020
    Assignee: ViiV Healthcare Company
    Inventors: Steven N. Goodman, Huan Wang, Douglas Mans, Matthew Kowalski
  • Patent number: 10426780
    Abstract: The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: October 1, 2019
    Assignee: ViiV Healthcare Company
    Inventor: Mark Richard Underwood
  • Publication number: 20190284208
    Abstract: The present invention is to provide a novol compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X? is a single bond, a hetoro atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound; including e.g., a tricyclic or tetracyclic compound.
    Type: Application
    Filed: May 1, 2019
    Publication date: September 19, 2019
    Applicants: Shionogi & Co., Ltd., ViiV Healthcare Company
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
  • Publication number: 20190152990
    Abstract: The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X? is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylrene in which the hetero atom group may intervene; R2 is optionally substituted aryl; Ra is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4and Z2 part taken together forms a ring, to forma polycyclic compound, including e.g., a tricyclic or tetracyclic compound.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 23, 2019
    Applicants: ViiV Healthcare Company
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA